Vol. 20/No. 24

Limb preservation is now the procedure of choice for the treatment of patients with bone cancer.

Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline

During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.

For the past 2 decades, clinical guidelines for the diagnosis and management of breast cancer have sought to clarify the definition of HER2 status, but several key questions remain.

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Investigators are attempting to advance the late-stage non–small cell lung cancer treatment paradigm by combining an emerging antimitotic modality with standard-of-care therapies in the phase III LUNAR trial.

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.